Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines

British Journal of Pharmacology

Volumn 142, Issue 6, 2004, Pages 921-932

  Douglas, Stephen A ^a   Naselsky, Diane ^a   Ao, Zhaohui ^a   Disa, Jyoti ^a   Herold, Christopher L ^a   Lynch, Frank ^b   Aiyar, Nambi V ^a  

^a GLAXOSMITHKLINE   (United States)

^b QualTek Molecular Laboratories Inc   (United States)

Author keywords

G protein coupled receptor; GPR14; Rhabdomyosarcoma; Skeletal muscle; Urotensin II; UT

Indexed keywords

ACETAMIDOMETHYLUROTENSIN II[5,10 CYSTEINE]; CALCIUM ION; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; PHOSPHOLIPASE C; UNCLASSIFIED DRUG; UROTENSIN; UROTENSIN II; UROTENSIN II RECEPTOR; UROTENSIN II[4-11];

ANIMAL CELL; ARTICLE; BINDING KINETICS; BINDING SITE; CALCIUM MOBILIZATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG MECHANISM; DRUG RECEPTOR BINDING; FISH; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAMMAL; NONHUMAN; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIMATE; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; RHABDOMYOSARCOMA; SKELETAL MUSCLE; SPECIES DIFFERENCE;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; BLOTTING, NORTHERN; CALCITONIN GENE-RELATED PEPTIDE; CALCIUM; CELL LINE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION PROFILING; HELA CELLS; HUMANS; HYPOTHALAMIC HORMONES; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SPACE; IODINE RADIOISOTOPES; KINETICS; MALE; MELANINS; NEUROPEPTIDE Y; NEUROPHYSINS; PERTUSSIS TOXIN; PITUITARY HORMONES; PROTEIN PRECURSORS; RADIOLIGAND ASSAY; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; THAPSIGARGIN; UROTENSINS; VASOPRESSINS;

EID: 3843053683     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705743     Document Type: Article

References (52)

1. AMES, R.S., SARAU, H.M., CHAMBERS, J.K., WILLETTE, R.N., AIYAR, N.V., ROMANIC, A.M., LOUDEN, C.S., FOLEY, J.J., SAUERMELCH, C.F., COATNEY, R.W., AO, Z., DISA, J., HOLMES, S.D., STADEL, J.M., MARTIN, J.D., LIU, W.-S.,. GLOVER, G.I., WILSON, S., MCNULTY, D.E., ELLIS, C.E., ELSHOURBAGY, N.A., SHABON, U., TRILL, J.J., HAY, D.W.P., OHLSTEIN, E.H., BERGSMA, D.J. & DOUGLAS, S.A. (1999). Human urotensin-II: a potent vasoconstrictor and agonist for an orphan receptor. Nature, 401, 282-286.
2. BERN, H.A. & LEDERIS, K. (1969). A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts. J. Endocrinol., 45, xi-xii.
3. BERN, H.A., PEARSON, D., LARSON, B.A. & NISHIOKA, R.S. (1985). Neurohormones from fish tails: the caudal neurosecretory system I: 'Urophysiology' and the caudal neurosecretory system of fishes. Rec. Prog Horm. Res., 41, 533-552.
4. BHASKARAN, R., ARUNKUMAR, A.I. & YU, C. (1994). NMR and dynamic simulated annealing studies on the solution conformation of urotensin II. Biochim. Biophys. Acta, 1199, 115-122.
5. BOTTRILL, F.E., DOUGLAS, S.A. HILEY, C.R. & WHITE, R. (2000). Human U-II is an endothelium-dependent vasodilator in rat small arteries. Br. J. Pharmacol., 130, 1865-1870.
6. BRAILOIU, E., BRAILOIU, C.G., MIYAMOTO, M.D. & DUN, N.J. (2003). The vasoactive peptide urotensin II stimulates spontaneous release from frog motor nerve terminals. Br. J. Pharmacol., 138, 1580-1588.
7. CHARTREL, N., CONLON, J.M., COLLIN, F., BRAUN, B., WAUGH, D., VALLARINO, M. & VAUDRY, H. (1998). Urotensin II in the central nervous system of the frog Rana ridibunda: biochemical characterization and immunohistochemical localization. Ann. N.Y. Acad. Sci., 839, 506-507.
8. CLARK, S.D., NOTHACKER, H.P., WANG, Z., SAITO, Y., LESLIE, P.M. & CIVELLI, O. (2001). The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat. Brain Res., 923, 120-127.
9. CONLON, J.M., TOSTIVINT, H. & VAUDRY, H. (1997). Somatostatin-and urotensin II-related peptides: molecular diversity and evolutionary perspectives. Reg. Pept., 69, 95-103.
10. CONLON, J.M., YANO, K., WAUGH, D. & HAZON, N. (1996). Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J. Exp. Zool., 275, 226-238.
11. COULOUARN, Y., FERNEX, C., JEGOU, S., HENDERSON, C.E., VAUDRY, H. & LIHRMANN, I. (2001). Specific expression of the urotensin II gene in sacral motoneurons of developing rat spinal cord. Mech. Dev., 101, 187-190.
12. COY, D.H., ROSSOWSKI, W.J., CHENG, B.L., HOCART, S.J. & TAYLOR, J.E. (2000). Novel urotensin-II (UII) antagonists point to multiple receptor involvement in UII bioactivity. Reg. Pept., 94, 48.
13. COY, D.H., ROSSOWSKI, W.J., CHENG, B.L. & TAYLOR, J.E. (2002). Structural requirements at the N-terminus of urotensin octapeptides. Peptides, 23, 2259-2264.
14. CROSTON, G.E., OLSSON, R., CURRIER, E.A., BURSTEIN, E.S., WEINER, D., NASH, N., SEVERANCE, D., ALLENMARK, S.G., THUNBERG, L., MA, J.-N., MOHELL, N., O'DOWD, B., BRANN, M.R. & HACKSELL, U. (2002). Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954). J. Med. Chem., 45, 4950-4953.
15. DE GARAVILLA, L., QI, J., SANTULLI, R., ANDRADE-GORDON, P. & ABRAHAM, W.M. (2001). Inhalation of urotensin-II increases airway resistance in sheep. Am. J. Resp. Crit. Care Med., 163, A924.
16. DOUGLAS, S.A. (2003). Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'. Curr. Opin. Pharmacol., 3, 159-167.
17. DOUGLAS, S.A. & OHLSTEIN, E.H. (2000). Urotensin receptors. In: The IUPHAR Compendium of Receptor Characterization and Classification, ed. Girdlestone, D. pp. 365-372. London: IUPHAR Media.
18. DOUGLAS, S.A. & OHLSTEIN, E.H. (2001). Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc. Med., 10, 229-237.
19. DOUGLAS, S.A., SULPIZIO, A.C., PIERCY, V., SARAU, H.M., AMES, R.S., AIYAR, N.V., OHLSTEIN, E.H. & WILLETTE, R.N. (2000). Differential vasoconstrictor activity of human U-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset, and cynomolgus monkey. Br. J. Pharmacol., 131, 1262-1274.
20. DUN, S.L., BRAILOIU, G.C., YANG, J., CHANG, J.K. & DUN, N.J. (2001). Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat. Neurosci. Lett., 305, 9-12.
21. ELSHOURBAGY, N., DOUGLAS, S.A., SHABON, U., HARRISON, S., DUDDY, G., SECHLER, J.L., AO, Z., MALEEFF, B.E., NASELSKY, D., DISA, J. & AIYAR, N.V. (2002). Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br. J. Pharmacol., 136, 9-22.
22. FILIPEANU, C.M., BRAILOIU, E., LE DUN, S. & DUN, N.J. (2002). Urotensin-II regulates intracellular calcium in dissociated rat spinal cord neurons. J. Neurochem., 83, 879-884.
23. FLOHR, S., KURZ, M., KOSTENIS, E., BRKOVICH, A., FOURNIER, A. & KLABUNDE, T. (2002). Identification of nonpeptide Urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin-II. J. Med. Chem., 45, 1799-1805.
24. GARTLON, J., PARKER, F., HARRISON, D.C., DOUGLAS, S.A., ASHMEADE, T.E., RILEY, G.J., HUGHES, Z.A., TAYLOR, S.G., MUNTON, R.P., HAGAN, J.J., HUNTER, A.J. & JONES, D.N.C. (2001). Central effects of human U-II following i.c.v. administration in rats. Psychopharmacology, 155, 426-433.
25. GIBSON, A. (1987). Complex effects of Gillichthys urotensin II on rat aortic strips. Br. J. Pharmacol., 91, 205-212.
26. GONZALEZ, G.C., MARTINEZ-PADRÓN, M., LEDERIS, K. & LUKOWIAK, K. (1992). Distribution and coexistence of urotensin I and urotensin II peptides in the cerebral ganglia of Aplysia californica. Peptides, 13, 695-703.
27. GRIECO, P., CAROTENUTO, A., CAMPIGLIA, P., ZAMPELLI, E., PATACCHINI, R., MAGGI, C.A., NOVELLINO, E. & ROVERO, P. (2002). A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J. Med. Chem., 45, 4391-4394.
28. HAY, D.W.P., LUTTMANN, M.A. & DOUGLAS, S.A. (2000). Human U-II is a potent spasmogen of primate airway smooth muscle. Br. J. Pharmacol., 131, 10-12.
29. HORIE, S., YASUDA, S., TSURUMAKI, Y., SOMEYA, A., SAITO, T., OKUMA, Y., NOMURA, Y., HIRABAYASHI, T. & MURAYAMA, T. (2003). Contraction of isolated guinea-pig ileum by urotensin II via activation of ganglionic cholinergic neurons and acetylcholine release. Neuropharmacology, 45, 1019-1027.
30. ITOH, H., MCMASTER, D. & LEDERIS, K. (1988). Functional receptors for fish neuropeptide urotensin II in major rat arteries Eur. J. Pharmacol., 149, 61-66.
31. KINNEY, W.A., ALMOND JR, H.R., QI, J., SMITH, C.E., SANTULLI, R.J., DE GARAVILLA, L., ANDRADE-GORDON, P., CHO, D.S., EVERSON, A.M., FEINSTEIN, M.A., LEUNG, P.A. & MARYANOFF, B.E. (2002). Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew. Chem. Int. Ed. Engl., 41, 2940-2944.
32. LABARRÈRE, P., CHATENET, D., LEPRINCE, J., MARIONNEAU, C., LOIRAND, G., TONON, M.-C., DUBESSY, C., SCALBERT, E., PFEIFFER, B., RENARD, P., CALAS, B., PACAUD, P. & VAUDRY, H. (2003). Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. J. Enz. Inhib. Med. Chem., 18, 77-88.
33. LIU, Q., PONG, S.S., ZENG, Z., ZHANG, Q., HOWARD, A.D., WILLIAMS JR, D.L., DAVIDOFF, M., WANG, R., AUSTIN, C.P., MCDONALD, T.P., BAI, C., GEORGE, S.R., EVANS, J.F. & CASKEY, T. (1999). Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem. Biophys. Res. Commun., 266, 174-178.
34. LORETZ, C.A., HOWARD, M.E. & SIEGEL, A.J. (1985). Ion transport in goby intestine: cellular mechanism of urotensin II stimulation. Am. J. Physiol., 249, G284-G293.
35. MAGUIRE, J.J., KUC, R.E. & DAVENPORT, A.P. (2000). Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol., 131, 441-446.
36. MORI M., SUGO, T., ABE, M., SHIMOMURA, Y., KURIHARA, M., KITADA, C., KIKUCHI, K., SHITANI, Y., KUROKAWA, T., ONDA, H., NISHIMURA, O. & FUJINO, M. (1999). Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem. Biophys. Res. Commun., 265, 123-129.
37. NOTHACKER, H.-P., WANG, Z., MCNEILL, A.M., SAITO, Y., MERTEN, S., O'DOWD, B., DUCKLES, S.P. & CIVELLI, O. (1999). Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat. Cell Biol., 1, 383-385.
38. RIVAS, R.J., NISHIOKA, R.S. & BERN, H.A. (1986). In vitro effects of somatostatin and urotensin II on prolactin and growth hormone secretion in tilapia, Oreochromis mossambicus. Gen. Comp. Endocrinol, 63, 245-251.
39. ROBERTS, W.M., DOUGLASS, E.C., PEIPER, S.C., HOUGHTON, P.J. & LOOK, A.T. (1989). Amplification of the gli gene in childhood sarcomas. Cancer Res., 49, 5407-5413.
40. ROSSOWSKI, W.J., CHENG, B.-L., TAYLOR, J.E., DATTA, R. & COY, D.H. (2002). Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur. J. Pharmacol., 438, 159-170.
41. RUSSELL, F.D., MOLENAAR, P. & O'BRIEN, D.M. (2001). Cardiostimulant effects of U-II in human heart in vitro. Br. J. Pharmacol., 132, 5-9.
42. SAETRUM-OPGAARD, O.S., NOTHACKER, H., EHLERT, F.J. & KRAUSE, D.N. (2000). Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur. J. Pharmacol., 406, 265-271.
43. SAUZEAU, V, LE MELLIONNEC, E., BERTOGLIO, J., SCALBERT, E., PACAUD, P. & LOIRAND, G. (2001). Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ. Res., 88, 1102-1104.
44. SHERIDAN, M.A. & BERN, H.A. (1936). Both somatostatin and the caudal neuropeptide, urotensin II, stimulate lipid mobilization from coho salmon liver incubated in vitro. Reg. Pept., 14, 333-344.
45. SILVESTRE, R.A., RODRIGUEZ-GALLARDO, J., EGIDO, E.M. & MARCO, J. (2001). Inhibition of insulin release by urotensin II: a study on the perfused rat pancreas. Horm. Metab. Res., 33, 379-381.
46. STIRRAT, A., GALLAGHER, M., DOUGLAS, S.A., OHLSTEIN, E.H., KIRK, A., BERRY, C., RICHARDSON, M. & MACLEAN, M.R. (2001). Potent vasodilator responses to human U-II in human pulmonary and abdominal resistance arteries: comparison with adrenomedullin and other vasodilators in pulmonary arteries. Am. J. Physiol, 280, H925-H928.
47. STRATTON, M.R., REEVES, B.R. & COOPER, C.S. (1989). Misidentified cell. Nature, 337, 311-312.
48. TAL, M., AMMAR, D.A., KARPUJ, M., KRIZHANOVSKY, V., NAIM, M. & THOMPSON, D.A. (1995). A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochem. Biophys. Res. Commun., 209, 752-759.
49. TZANIDIS, A., HANNAN, R.D., THOMAS, W.G., ONAN, D., AUTELITANO, D.J., SEE, F., KELLY, D.J., GILBERT, R.E. & KRUM, H. (2003). Direct actions of urotensin-II on the heart: implications for cardiac fibrosis and hypertrophy. Circ. Res., 93, 246-253.
50. WATANABE, T., KOBA, S., KATAGIRI, T., PAKALA, R. & BENEDICT, C.R. (2002). Lysophosphatidylcholine potentiates the mitogenic effect of various vasoactive compounds on rabbit aortic smooth muscle cells. Jap. Heart J., 43, 409-416.
51. WATSON, A.M., LAMBERT, G.W., SMITH, K.J. & MAY, C.N. (2003). Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension, 42, 373-379.
52. ZILTENER, P., MUELLER, C., HAENIG, B., SCHERZ, M.W. & NAYLER, O. (2002). Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines. J. Recept. Signal Transduct. Res., 22, 155-168.